{"id":13445,"date":"2026-02-19T23:23:17","date_gmt":"2026-02-19T23:23:17","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/13445\/"},"modified":"2026-02-19T23:23:17","modified_gmt":"2026-02-19T23:23:17","slug":"swiss-ministers-discuss-tariff-impacts-with-pharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/13445\/","title":{"rendered":"Swiss Ministers Discuss Tariff Impacts with Pharma"},"content":{"rendered":"<p>Impact of U.S. Tariffs on Swiss Pharmaceuticals<\/p>\n<p>ZURICH (Reuters) -Swiss ministers have met with senior executives of pharmaceutical companies Roche and Novartis to discuss the outlook for the sector under current U.S. trade policy, the government said on Thursday.<\/p>\n<p>President Donald Trump has imposed U.S. import tariffs of 39% on Swiss goods, one of the highest rates worldwide, though pharmaceutical firms have so far been spared the duties.<\/p>\n<p>The Trump administration is carrying out a probe into pharmaceutical imports, after which tariffs could follow.<\/p>\n<p>Meeting Overview<\/p>\n<p>Swiss Interior Minister Elisabeth Baume-Schneider and Economy Minister Guy Parmelin met on Thursday morning with Roche Chairman Severin Schwan and Patrick Horber, head of the international unit for Novartis, the government said.<\/p>\n<p>Confidential Discussions<\/p>\n<p>&#8220;The participants of the meeting exchanged their views on the current situation in the pharmaceutical industry against the backdrop of discussions about the tariffs imposed by the United States,&#8221; the Interior Ministry said in a statement.<\/p>\n<p>Future Roundtable Plans<\/p>\n<p>What was discussed is confidential, the ministry said, noting that the ministers were organising a roundtable discussion with the pharmaceutical industry in September.<\/p>\n<p> (Writing by Dave Graham. Additional reporting by Ariane Luthi. Editing by Mark Potter)<\/p>\n","protected":false},"excerpt":{"rendered":"Impact of U.S. Tariffs on Swiss Pharmaceuticals ZURICH (Reuters) -Swiss ministers have met with senior executives of pharmaceutical&hellip;\n","protected":false},"author":2,"featured_media":13446,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[1983,4587,134,9847,9848,9846],"class_list":{"0":"post-13445","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-import-tariffs","9":"tag-pharmaceutical-industry","10":"tag-roche","11":"tag-roche-novartis","12":"tag-swiss-ministers-meeting","13":"tag-u-s-trade-policy"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/13445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=13445"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/13445\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/13446"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=13445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=13445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=13445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}